Condition (MeSH)
Thrombocytopenia, Neonatal Alloimmune
ClinicalTrials.gov lists 15 trials for Thrombocytopenia, Neonatal Alloimmune or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
15 of the 15 trials are tagged with Thrombocytopenia, Neonatal Alloimmune itself; the rest are tagged with a narrower condition beneath it.
When did Thrombocytopenia, Neonatal Alloimmune trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 2 |
| 2022 | 2 |
| 2021 | 1 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Thrombocytopenia, Neonatal Alloimmune trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
| Not applicable | 1 |
| Observational | 11 |
How many Thrombocytopenia, Neonatal Alloimmune trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Completed | 6 |
| Terminated | 1 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Thrombocytopenia, Neonatal Alloimmune trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 2 |
| Rallybio | 2 |
| Prophylix Pharma AS | 1 |
Which drugs are being tested for Thrombocytopenia, Neonatal Alloimmune? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nipocalimab | 2 |
| Platelets | 1 |
| Prednisone | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Intravenous Immunoglobulins | 1 |
| Platelet Transfusion | 1 |
| Anti-(integrin beta-3) human monoclonal antibody | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Thrombocytopenia, Neonatal Alloimmune? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Children Newly Diagnosed with Fetal and Neonatal Alloimmune Thrombocytopenia: Neurodevelopmental Outcome at School Age. | The Journal of pediatrics | 2023 | Yes |
| HIP (HPA-screening in pregnancy) study: protocol of a nationwide, prospective and observational study to assess incidence and natural history of fetal/neonatal alloimmune thrombocytopenia and identifying pregnancies at risk. | BMJ open | 2020 | Yes |
| Perinatal Outcome and Long-Term Neurodevelopment after Intracranial Haemorrhage due to Fetal and Neonatal Alloimmune Thrombocytopenia. | Fetal diagnosis and therapy | 2019 | Yes |
| Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. | Blood | 2019 | Yes |
| Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. | Blood | 2017 | Yes |
Showing 5 of 13 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.